Skip to main content
The William Harvey Research Institute - Faculty of Medicine and Dentistry
  1. WHRI
  2. People
  3. Academic staff
  4. Items

Professor Anthony Mathur

Anthony

Centre for Cardiovascular Medicine and Device Innovation, Centre Lead

Centre: Cardiovascular Medicine and Devices

Email: a.mathur@qmul.ac.uk
Telephone: +44(0) 20 3765 8740

Profile

I divide my time equally between clinical work and translational medicine and research. My research focuses on examining the role of biologics (stem cells, gene therapy, cellular bioenergetics, megakaryocyte biology) in the treatment of cardiovascular disease. As the Clinical Director for Interventional Cardiology at Barts Health, my clinical work is directed towards the management of patients who have failed conventional therapy for heart failure and angina. Furthermore, I Chair the ESC Task Force on stem cells in cardiovascular disease and, previously, I Chaired the British Cardiac Stem Cells Collaborative set up by Prof. John Martin. I also lead the Compassionate Stem Cell Treatment Unit for patients with cardiac disease at Barts Heart Centre.

Within the Centre for Cardiovascular Medicine and Device Innovation, I lead the Cardiovascular Devices Hub (CVD HUB). The CVDHub supports collaborations between academic, clinical, engineering and industrial innovators to develop clinically and commercially viable cardiovascular devices. This novel, cross-speciality unit helps small to medium enterprises (SMEs) over the hurdles involved in taking innovations to human trials. Within device innovation, I focus on first-in-man trials, digital technologies (e.g Avatars) and artificial intelligence.

Research

I lead a collaborative group with several investigators (including Prof. John Martin (UCL), Prof. Amrita Ahluwalia (Queen Mary), Prof. Andreas Baumbach (Queen Mary) and Prof. Alexandra Lansky (Yale) seeking to address the role of biologics in the treatment of cardiovascular disease; translating basic research into therapeutic approaches in man. My interventional cardiology research aims to develop new treatments for patients that fall outside the remit of current recognised therapies. I have designed a series of trials addressing the use of stem cells in the treatment of cardiovascular disease, and am currently the CI for one of the first Phase III clinical trials of cell therapy in acute myocardial infarction. I am also interested in the use of advanced cardiac imaging, and established the first Cardiac CMR service at Barts Health.

Publications

  • Bennett J, Thornton GD, Nitsche C et al. (2024). Left Ventricular Hypertrophy in Aortic Stenosis: Early Cell and Matrix Regression 2 Months Post-Aortic Valve Replacement. nameOfConference


  • Ramasamy A, Parasa R, Sokooti H et al. (publicationYear). Computed tomography versus near-infrared spectroscopy for the assessment of coronary atherosclerosis.. nameOfConference


  • Kelham M, Beirne A-M, Rathod KS et al. (2024). CTCA Prior to Invasive Coronary Angiography in Patients With Previous Bypass Surgery: Patient-Related Outcomes, Imaging Resource Utilization, and Cardiac Events at 3 Years From the BYPASS-CTCA Trial. nameOfConference


    QMRO: qmroHref
  • Sayers M, Rathod K, Akhtar M et al. (2024). Prognostic significance of coexistent coronary artery disease in patients undergoing transcatheter aortic valve implantation for aortic stenosis. nameOfConference


    QMRO: qmroHref
  • Rathod KS, Mathur A, Shabbir A et al. (2024). The NITRATE-OCT study-inorganic nitrate reduces in-stent restenosis in patients with stable coronary artery disease: a double-blind, randomised controlled trial. nameOfConference


  • Leikas AJ, Hartikainen JEK, Kastrup J et al. (2024). Clinical development and proof of principle testing of new regenerative vascular endothelial growth factor-D therapy for refractory angina: rationale and design of the phase 2 ReGenHeart trial. nameOfConference


  • Patel KP, Rathod KS, Lansky AJ et al. (2024). Cerebrovascular Events in Patients Undergoing Transcatheter Aortic Valve Replacement: A Review. nameOfConference


  • Bloch MJ, Kirtane AJ, Azizi M et al. (2024). 36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO. nameOfConference


  • Kelham M, Beirne A-M, Rathod KS et al. (2024). OP1 The use of computed tomography coronary angiography as a gatekeeper to predict the need for invasive coronary angiography in patients with previous CABG presenting with acute coronary syndromes. OP1 The use of computed tomography coronary angiography as a gatekeeper to predict the need for invasive coronary angiography in patients with previous CABG presenting with acute coronary syndromes


    QMRO: qmroHref
  • Vyas R, Kelham M, Beirne A-M et al. (2024). OP5 Diagnostic accuracy of CTCA for graft and native disease assessment in patients with previous CABG: insights from the BYPASS-CTCA trial. OP5 Diagnostic accuracy of CTCA for graft and native disease assessment in patients with previous CABG: insights from the BYPASS-CTCA trial


    QMRO: qmroHref
View Profile Publication Page

Sponsors

 

News

Back to top